Leuthold Group LLC Invests $3.40 Million in Regeneron Pharmaceuticals, Inc. $REGN

Leuthold Group LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to its most recent disclosure with the SEC. The firm bought 6,044 shares of the biopharmaceutical company’s stock, valued at approximately $3,398,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Savvy Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 22.5% in the third quarter. Savvy Advisors Inc. now owns 1,942 shares of the biopharmaceutical company’s stock valued at $1,092,000 after acquiring an additional 357 shares in the last quarter. LSV Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $31,262,000. Skylands Capital LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $1,161,000. Cibc World Market Inc. increased its position in Regeneron Pharmaceuticals by 232.3% during the third quarter. Cibc World Market Inc. now owns 15,733 shares of the biopharmaceutical company’s stock worth $8,846,000 after buying an additional 10,999 shares during the period. Finally, Caprock Group LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter valued at approximately $1,471,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the sale, the director owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 3,636 shares of company stock worth $2,862,920. 7.02% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of recent research reports. HSBC raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 24th. Citigroup raised their price target on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday. UBS Group increased their price objective on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Finally, Canaccord Genuity Group boosted their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a report on Thursday, December 4th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $793.81.

Regeneron Pharmaceuticals Trading Up 3.2%

Shares of REGN stock opened at $778.97 on Thursday. The business’s fifty day moving average price is $759.25 and its 200 day moving average price is $662.51. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The firm has a market capitalization of $81.87 billion, a PE ratio of 18.74, a P/E/G ratio of 2.03 and a beta of 0.40. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the company earned $12.07 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be issued a dividend of $0.94 per share. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.47%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.